Significant Transplantation-Related Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem Cell Transplantation

Biol Blood Marrow Transplant. 2015 Oct;21(10):1802-7. doi: 10.1016/j.bbmt.2015.06.015. Epub 2015 Jun 25.

Abstract

Respiratory viral infections (RVI) are important in hematopoietic stem cell transplantations (HSCT) and knowledge regarding incidence, morbidity, mortality, and long-term pulmonary complications is limited. We report a study to evaluate incidence and outcomes, both short and long-term, of RVI in children receiving HSCT. Between January 2000 and December 2012, 844 patients underwent hematopoietic stem cell transplantation (HSCT) at the Hospital for Sick Children: 491 were allogeneic and 353 were autologous. When screening for causes of death in the first year after HSCT in the 844 patients, we found that RVI as a cause of death was only evident in the first 100 days after HSCT. Fifty-four (6.5%) patients were found to have an RVI within the first 100 days after HSCT (allogeneic = 32, autologous = 22). Upper and lower respiratory tract infections were documented in 31 (57%) and 23 (43%) patients, respectively. Viruses were parainfluenza (35%), respiratory syncytial virus (28%), influenza (22%), adenovirus (7%), human metapneumovirus (4%), coronavirus (2%), and rhinovirus (2%). Three patients relapsed with their primary disease before day 100 and were excluded. The overall mortality for the remaining 51 patients was 10% (allogeneic = 4, autologous = 1). All 5 deaths were directly attributable to RVI and all 5 deaths occurred in patients with a lower respiratory tract infection. The remaining patients were followed for a median of 4.3 years (range, 1.4 to 11.8) and no chronic pulmonary complications were observed. A clear seasonal pattern for contracting RVI was evident with 65% of total RVI occurring between October and March (35 of 427 versus 19 of 417, P = .03). Given the significant mortality from RVI and the challenges in preventing them, choosing the time to start HSCT, whenever possible, may help prevent RVI and improve outcomes.

Keywords: Children; Hematopoietic stem cell transplantation; Mortality; Respiratory virus infection.

MeSH terms

  • Adolescent
  • Allografts
  • Antibiotic Prophylaxis
  • Antiviral Agents / therapeutic use
  • Canada / epidemiology
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Environment, Controlled
  • Febrile Neutropenia / drug therapy
  • Female
  • Follow-Up Studies
  • Genetic Diseases, Inborn / therapy
  • Hematologic Diseases / therapy
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunocompromised Host
  • Incidence
  • Infant
  • Infant, Newborn
  • Lymphohistiocytosis, Hemophagocytic / therapy
  • Male
  • Neoplasms / therapy
  • Nutritional Support
  • Pneumonia, Viral / mortality
  • Pneumonia, Viral / therapy
  • Pneumonia, Viral / virology
  • Respiratory Insufficiency / etiology
  • Respiratory Insufficiency / mortality
  • Respiratory Tract Infections / diagnosis
  • Respiratory Tract Infections / mortality*
  • Respiratory Tract Infections / therapy
  • Respiratory Tract Infections / virology
  • Retrospective Studies
  • Risk
  • Transplantation, Autologous
  • Treatment Outcome
  • Virus Diseases / mortality*
  • Virus Diseases / virology

Substances

  • Antiviral Agents